BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou H, Luo P, Li P, Wang G, Yi X, Fu Z, Sun X, Cui B, Zhu L, Zhu S. Bariatric Surgery Improves Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Obes Surg 2022. [PMID: 35386040 DOI: 10.1007/s11695-022-06011-1] [Reference Citation Analysis]
2 Willuweit MGA, Lopes AJ, Ferreira AS. Development of a multivariable prediction model of functional exercise capacity in liver transplant recipients. Journal of Liver Transplantation 2022;6:100067. [DOI: 10.1016/j.liver.2021.100067] [Reference Citation Analysis]
3 Flores-Guerrero JL, Post A, van Dijk PR, Connelly MA, Garcia E, Navis G, Bakker SJL, Dullaart RPF. Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease. Liver Int 2021. [PMID: 33993608 DOI: 10.1111/liv.14963] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Mantovani A. GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss? Dig Liver Dis 2021;53:1673-4. [PMID: 34366254 DOI: 10.1016/j.dld.2021.07.013] [Reference Citation Analysis]
5 Huang YZ, Yang GY, Wang C, Chen XY, Zhang LL. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. World J Diabetes 2021; 12(9): 1576-1586 [PMID: 34630909 DOI: 10.4239/wjd.v12.i9.1576] [Reference Citation Analysis]
6 Fang Z, Dou G, Wang L. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Int J Biol Sci 2021;17:1851-63. [PMID: 33994867 DOI: 10.7150/ijbs.59588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2021:gutjnl-2021-324915. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Reference Citation Analysis]
8 Xin X, Cheng C, Bei-Yu C, Hong-Shan L, Hua-Jie T, Xin W, Zi-Ming A, Qin-Mei S, Yi-Yang H, Qin F. Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity. Front Nutr 2021;8:784354. [PMID: 34881283 DOI: 10.3389/fnut.2021.784354] [Reference Citation Analysis]
9 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
10 Liu M, Huang Q, Zhu Y, Chen L, Li Y, Gong Z, Ai K. Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100215] [Reference Citation Analysis]
11 Tang R, Li R, Li H, Ma XL, Du P, Yu XY, Ren L, Wang LL, Zheng WS. Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease. ACS Nano 2021. [PMID: 34705426 DOI: 10.1021/acsnano.1c02158] [Reference Citation Analysis]
12 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Reference Citation Analysis]
13 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
14 Sun Q, Niu Q, Guo Y, Zhuang Y, Li X, Liu J, Li N, Li Z, Huang F, Qiu Z. Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD. J Agric Food Chem 2021;69:8714-25. [PMID: 34323067 DOI: 10.1021/acs.jafc.1c03105] [Reference Citation Analysis]
15 Xie J, Huang H, Chen Y, Xu L, Xu C. Skipping breakfast is associated with an increased long-term cardiovascular mortality in metabolic dysfunction-associated fatty liver disease (MAFLD) but not MAFLD-free individuals. Aliment Pharmacol Ther 2022;55:212-24. [PMID: 34877669 DOI: 10.1111/apt.16727] [Reference Citation Analysis]
16 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci 2021;22:4459. [PMID: 33923295 DOI: 10.3390/ijms22094459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci 2022;23:3107. [PMID: 35328527 DOI: 10.3390/ijms23063107] [Reference Citation Analysis]
18 Duan X, Lv J, Jiang H, Zheng K, Chen Y, Zhao E. Inflammatory Cytokines, Adipocytokines, and Th17/Treg Balance in Patients with Nonalcoholic Fatty Liver Disease following Administration of Dahuang Zhechong Pills. Genetics Research 2022;2022:1-5. [DOI: 10.1155/2022/8560831] [Reference Citation Analysis]
19 Marchesini G, Taylor R. Genes and lifestyle: Which of the two is more relevant in driving NAFLD progression? Dig Liver Dis 2021;53:1433-4. [PMID: 34509395 DOI: 10.1016/j.dld.2021.08.011] [Reference Citation Analysis]
20 Amerikanou C, Papada E, Gioxari A, Smyrnioudis I, Kleftaki SA, Valsamidou E, Bruns V, Banerjee R, Trivella MG, Milic N, Medić-Stojanoska M, Gastaldelli A, Kannt A, Dedoussis GV, Kaliora AC; MAST4HEALTH. Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action. Pharmacol Res 2021;171:105753. [PMID: 34224858 DOI: 10.1016/j.phrs.2021.105753] [Reference Citation Analysis]
21 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2021:S1590-8658(21)00214-0. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Reference Citation Analysis]
22 Zhou Y, Li R, Zheng Y, Song M, Zhang S, Sun Y, Wei M, Fan X. Diosgenin Ameliorates Non-alcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Related Lipid/Amino Acid Metabolism in High Fat Diet-Fed Rats. Front Pharmacol 2022;13:854790. [DOI: 10.3389/fphar.2022.854790] [Reference Citation Analysis]
23 Mantovani A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. Hepatobiliary Surg Nutr 2021;10:518-21. [PMID: 34430533 DOI: 10.21037/hbsn-2021-13] [Reference Citation Analysis]
24 Brodosi L, Marchignoli F, Marchesini G, Petroni ML. Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. Expert Opin Pharmacother 2021;:1-5. [PMID: 34541981 DOI: 10.1080/14656566.2021.1980538] [Reference Citation Analysis]
25 Ma Y, Sun K, Cao J, Qin X, Shi J, Li H, Zhang J, Zhang T. Acupuncture combined with Chinese herbal medicine on non-alcoholic fatty liver disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e28083. [PMID: 34941049 DOI: 10.1097/MD.0000000000028083] [Reference Citation Analysis]
26 Ore A, Akinloye OA. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions. Medicina (Kaunas) 2021;57:822. [PMID: 34441028 DOI: 10.3390/medicina57080822] [Reference Citation Analysis]
27 Zhang S, Meng G, Zhang Q, Liu L, Wu H, Gu Y, Wang Y, Zhang T, Wang X, Zhang J, Sun S, Wang X, Zhou M, Jia Q, Song K, Wang Y, Qi L, Niu K. Inflammatory potential of diet and risk of nonalcoholic fatty liver disease: a prospective cohort study. Eur J Clin Nutr 2022. [PMID: 35079162 DOI: 10.1038/s41430-022-01069-7] [Reference Citation Analysis]
28 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2021. [PMID: 34914079 DOI: 10.1007/s40519-021-01287-1] [Reference Citation Analysis]
29 Jamialahmadi T, Nematy M, Abdalla M, Jangjoo A, Goshayeshi L, Kroh M, Moallem SA, Abbasifard M, Sathyapalan T, Sahebkar A, Valdés-ramos R. The Predictive Role of Parathyroid Hormone for Nonalcoholic Fatty Liver Disease following Bariatric Surgery. Journal of Nutrition and Metabolism 2022;2022:1-6. [DOI: 10.1155/2022/7319742] [Reference Citation Analysis]
30 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Reference Citation Analysis]
31 Napoli R, Avogaro A, Formoso G, Piro S, Purrello F, Targher G, Consoli A. Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutr Metab Cardiovasc Dis 2021;31:3257-70. [PMID: 34627692 DOI: 10.1016/j.numecd.2021.08.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]